Malignant Melanoma – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of malignant melanoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of malignant melanoma for each country as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.

Clarivate Epidemiology’s malignant melanoma forecast will answer the following questions:

• How will improvements in survival change the number of people diagnosed with malignant melanoma each year?
• How will the declining risk of recurrence change the number of people living with malignant melanoma?
• Of all people diagnosed with malignant melanoma, how many in each of the major mature pharmaceutical markets are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of malignant melanoma over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the countries considered in this report. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

Clarivate Epidemiology provides at least 10 years of forecast data for the following malignant melanoma patient populations:

• Diagnosed incident cases by stage.
• Diagnosed incident cases by resectability status.
• Diagnosed prevalent cases by resectability status.
• First locoregional resectable recurrence.
• Second locoregional resectable recurrence.
• Unresectable metastatic recurrence.
• Adjuvant BRAF+ve and BRAF-ve drug-treatable population.
• First-line unresectable BRAF+ve and BRAF-ve DTP subpopulation(s).
• Other lines of treatment.

… and many more (details available on request).

Note: Coverage may vary by country and region.